Teva Pharmaceutical (TEVA) Slammed Early on FY13 Warning
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Teva Pharma (TEVA) Guides FY13 EPS, Revs Below Expectations
November 30, 2012 7:02 AM ESTTeva Pharmaceutical Industries (NYSE: TEVA) said it expects FY13 adjusted EPS of $4.85 - $5.15, versus the consensus of $5.63.
The company is targeting revs of $19.5 - $20.5 billion, versus the consensus of $20.82 billion.... More
